{"id":"Z19","lang":"zh","question":"台灣浩鼎的 OBI-992 是什麼 ADC？美國臨床試驗登錄進度到哪？","answer":[{"text":"OBI-992 是以 TROP2 為標靶、透過可切割胜肽連接子連接 exatecan 的 ADC。","fact_ids":["f1"]},{"text":"ClinicalTrials.gov 登錄 NCT06480240 為晚期實體腫瘤的第 1/2 期試驗，含美國試驗中心，狀態為進行中但不再收案；本次讀取的最後公開更新日期是 2025 年 8 月 8 日。","fact_ids":["f2","f3","f4","f5"]}],"facts":[{"id":"f1","claim":"ADC composition","value":"TROP2-targeting antibody, cleavable peptide linker and exatecan","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"Anti-TROP2 antibody drug conjugate"},{"id":"f2","claim":"Registered trial","value":"NCT06480240; Phase 1/2; advanced solid tumors","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"NCT06480240"},{"id":"f3","claim":"Registry status","value":"ACTIVE_NOT_RECRUITING","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"ACTIVE_NOT_RECRUITING"},{"id":"f4","claim":"Last posted update","value":"2025-08-08","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"2025-08-08"},{"id":"f5","claim":"US study locations","value":"美國試驗中心／United States study sites","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"United States"}],"undisclosed":{"text":"本卡讀取的公開登錄未刊出試驗結果，也沒有揭露 OBI-992 的確定上市核准日期。","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","as_of":"2026-10-22","quote":"NCT06480240","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["登錄最後更新早於本次查核；不能以查核日當成試驗狀態更新日。"],"registry_results_posted":false}